Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q1 FY24 results · Apr–Jun 2023
Cohance Lifesciences reported revenue from operations of ₹347.55 crore (up 2.6% from Q1 FY23) and net profit of ₹120.59 crore (up 12.1% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 347.55 | 338.80 | +2.6% | 369.36 | −5.9% |
| Other income | 10.67 | 11.03 | −3.3% | 11.40 | −6.4% |
| Total income | 358.22 | 349.83 | +2.4% | 380.76 | −5.9% |
| Profit before tax | 163.94 | 148.96 | +10.1% | 166.21 | −1.4% |
| Net profit for the period | 120.59 | 107.54 | +12.1% | 123.97 | −2.7% |
| EPS, basic (₹) | 4.74 | 4.22 | +12.3% | 4.87 | −2.7% |
| Net margin (%) | 34.7 | 31.7 | 33.6 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 344.03 | 338.80 | +1.5% | 364.39 | −5.6% |
| Other income | 10.06 | 10.90 | −7.7% | 10.75 | −6.5% |
| Total income | 354.08 | 349.70 | +1.3% | 375.14 | −5.6% |
| Profit before tax | 167.65 | 153.66 | +9.1% | 172.47 | −2.8% |
| Net profit for the period | 124.29 | 114.05 | +9.0% | 130.16 | −4.5% |
| EPS, basic (₹) | 4.88 | 4.48 | +8.9% | 5.11 | −4.5% |
| Net margin (%) | 36.1 | 33.7 | 35.7 |
Consolidated
- Filed with BSE
- 08 Aug 2023, 17:48 IST
- Board meeting
- 08 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Aug 2023, 17:48 IST
- Board meeting
- 08 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE